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1. Introduction 
Trachoma remains the leading cause of preventable corneal blindness worldwide and 
especially in the developing countries. It afflicts some of the poorest regions of the globe, 
predominantly in Africa and Asia. The disease is initiated in early childhood by repeated 
infection of the ocular surface by Chlamydia trachomatis. Initial clinical manifestation is a 
follicular conjunctivitis which if not treated on timely basis, may lead to conjunctival and 
eyelid scarring that may eventually result in corneal scarring and loss of vision. Despite 
the remarkable progress in our understanding of Chlamydial infection, the basic 
mechanisms involved in tissue damage, scarring and repeated episodes of conjunctivitis 
remain to be elucidated. However, over the past 2 decades, a remarkable reduction in the 
prevalence of active trachoma in poor countries has occurred due to the World Health 
Organization’s (WHO) program GET 2020 for the elimination of trachoma, with adoption 
of the SAFE strategy incorporating Surgery, Antibiotic treatment, Facial cleanliness and 
Environmental hygiene. Immunohistochemical studies of conjunctival biopsies from 
children with active trachoma demonstrate the presence of both humoral and cell-
mediated immune responses. Recurrent chronic inflammatory episodes cause 
conjunctivitis which leads to the development of conjunctival scarring/contractures, 
distorting the eyelids in the form of trichiasis and entropion. This compromises the cornea 
and blinding opacification often ensues. Since trachoma is a disease of poverty, 
overcrowding, and poor sanitation, active disease affects mainly children, but adults are 
at increased risk of scarring. Its prevalence is disproportionately high among women and 
children in poor rural communities.   
Improvement in socio-economic status/health facilities within the last 20 years has lead to 
the public awareness, prevention and treatment of bulk of active trachoma. In the active 
trachomatous conjunctivitis, macrophages may play an active role in conjunctival scarring 
by upregulated local production of extracellular matrix by the expression of the fibrogenic 
and angiogenic connective tissue growth factor. It is believed that the chronic 
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trachomatous follicular conjunctivitis may lead to canaliculitis, canalicular obstruction, 
dacryocystitis and nasolacrimal duct obstruction. Entropion has been found to be the 
most significant predictor of corneal opacity. Among the lacrimal complications of 
trachoma, dry eye syndrome, punctal phimosis, punctal occlusion, canalicular occlusion, 
nasolacrimal-duct obstruction, dacryocystitis, dacryocystocele, and dacryocutaneous 
fistula are the most common findings. Trachoma may cause dryness of the eye by 
decreasing mucus production and aqueous secretions. Severe cases of trachoma may lead 
to contracture of the conjunctiva, deeper tissues including Müller muscle and the tarsal 
plate, which supports the insertion of the levator aponeurosis. The upper eyelid of these 
patients may show eyelid retraction which also may show eyelid lag on patient’s down-
gaze. Four major eyelid complications: cicatricial entropion, eyelid retraction, secondary 
blepharospasm and brow ptosis may be seen. Entropion/trichiasis may be the most 
common with significant blinding complication. Eyelids of patients with inactive 
trachoma may be thickened. This thickening could be attributed to trachomatous changes 
in the conjunctiva and tarsus. Light microscopy studies of tarsal plates obtained during 
biopsies of tarsal plates and palpebral conjunctivae obtained from upper eyelids of 
patients with inactive trachoma show a thick and compact subepithelial fibrous 
membrane adherent to the tarsal plate. Other histopathologic findings include atrophy of 
the meibomian glands with thickening of the acinar basement membrane, loss of goblet 
cells, retention cysts, and hyaline degeneration of the tarsal plate with focal replacement 
by adipose tissue. 
The prevalence of active trachoma infection has dropped significantly in some African 
countries attributable to both improvements in socioeconomic standards and the training 
of village health workers and traditional birth attendants in eye care. Azithromycin oral 
single dose has been found to be safe and effective in children with active trachoma. 
However, patients who already have infection at young age continue to present with 
adnexal related complications of trachomatous scarring which continue to cause corneal 
scarring and visual loss. Management of trachomatous cicatricial entropion of the upper 
eye lid causing chronic conjunctivitis presents a difficult problem. Many surgical 
approaches have been developed to address it. Most effective surgery is full-thickness 
incision of the tarsal plate and rotation of the terminal tarsal strip 180 degrees. With the 
modified surgical technique, a combination of bilamellar tarsal margin rotation procedure 
with blepharoplasty may be advocated. With this technique, the eye lids as well as the 
normal eyelashes can be rotated away from the surface of the eye and eyes have adequate 
lid closure and regular lid margin. The modified technique prevents any overhanging 
baggy fold of skin at operation site. In developing countries, where manpower and other 
resources are limited and patient-load high, ophthalmic surgeons are recommended to 
choose a procedure that is simple, quick and effective. Surgery for entropion results in 
healing of superficial keratopathy, improved tear film stability. The realigned eyelid 
margin may spread tears evenly and efficiently, thus contributing to improvement of 
chronic conjunctivitis and vision.   
2. Trachoma in history 
The word "trachoma", derived from ancient Greek, means “rough eye”, due to the 
“cobblestone” appearance of the conjunctival lining of the globe as a result of reactive 
lymphoid follicles.1 Treatment of trachoma and its complications have been recorded in the 
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ancient Egyptian writings. It is reported that both Hippocrates and Galen, had access to 
ancient Egyptian methods of treating both acute as well as chronic complications of trachoma.1  
2.1 Trachoma: Extent of the problem 
Trachoma remains the leading infectious cause of ocular morbidity in some parts of the 
world.2,3 The disease is caused by an obligate intracellular bacterium Chlamydia trachomatis 
(C. trachomatis).4 The transmission of the disease occurs primarily in children during their 
early years of life.5 Repeated episodes of re-infection within the family members cause 
chronic conjunctivitis resulting in scarring in later years and continued loss of vision. The 
scarring is mostly in the conjunctiva and cornea but can affect nasolacrimal drainage system 
causing ocular complications as a result of its blockage. Eyelid scarring may result in 
distortion of the upper tarsal plate leading to trichiasis, entropion of eyelids and 
conjunctivitis. Chronic abnormality of the eyelids may cause corneal scaring, recurrent 
infections and decreased vision.6  
2.2 Clinical presentation of trachomatous conjunctivitis 
The initial response of an eye to infection with C. trachomatis is conjunctivitis involving the 
palpebral and bulbar conjunctiva.7,8 In these eyes, the conjunctiva may be inflamed, swollen 
along with papillary hypertrophy prominent in the palpebral conjunctiva (Figure 1). The 
initial conjunctival response may be followed by lymphoid follicle formation, most  
 
    
 
 
Fig. 1. Right upper eyelid of a child showing follicular reaction due to trachomatous 
conjunctivitis (upper right). Bilateral trachomatous conjunctivitis in another child with 
discharge (upper left). Intense follicular reaction in the right eye of a young child with 
trachomatous conjunctivitis (bottom figure). 
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commonly found on the palpebral conjunctiva as well as on the bulbar conjunctiva 
especially on at the limbus.6 After healing, these conjunctival follicles may result in Herbert's 
pits, named after an English ophthalmologist. These patients may be more prone to infection 
by other bacterial species resulting in secondary conjunctivitis and discharge. 
Active trachoma is characterized by a mucopurulent keratoconjunctivitis (Figure 1). The 
conjunctival surface of the upper eyelid shows a follicular and inflammatory response.9 The 
cornea may have limbal follicles, superior neovascularization (pannus), and punctate 
keratitis. Infection with C. trachomatis concurrently occurs in other extraocular mucous 
membranes, commonly the nasopharynx, leading to a nasal discharge. Follicular trachoma 
(designated TF in the WHO simplified trachoma grading scheme), is defined as the presence 
of 5 or more follicles at least 0.5 mm in diameter in the central part of the upper tarsal 
conjunctiva. Follicular trachoma indicates active disease. This form is most commonly found 
in children, with prevalence in those aged between 3 to 5 years of age children. The 
prevalence rapidly decreases in school-aged children as they leave the pool of re-infection. 
Follicles are germinal centers that primarily consist of lymphocytes and monocytes.10 
Involution of follicles at the limbus (corneoscleral border) give rise to the pathognomonic 
lesion of past active trachoma, Herbert’s pits. Intense inflammatory trachoma (designated TI 
in the WHO simplified trachoma grading scheme), is defined as pronounced inflammatory 
thickening of the upper tarsal conjunctiva that obscures more than one half of the normal 
deep tarsal vessels.  
During the intense inflammatory response, normally thin tarsal conjunctiva develops a 
velvety thickening. Papillae are visible under slit lamp examination (Figures 1). Intense 
inflammatory trachoma indicates an increased potential for significant conjunctival scarring 
and, hence, a higher ultimate risk of blinding disease. Surveying the prevalence of intense 
inflammatory trachoma in children can help in predicting the risk of future blinding 
trachoma in that cohort of children.5 Trachomatous scarring (designated TS in the WHO 
simplified trachoma grading scheme), indicates presence of easily visible scars in the tarsal 
conjunctiva (Figures 2,3). Trachomatous scarring indicates past inflammatory disease and a  
 
 
Fig. 2. An elderly patient with bilateral corneal scarring and upper eyelid retraction due to 
old trachoma 
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risk of future trichiasis. In the setting of more severe scarring, there is higher risk of subsequent 
trichiasis.8 This form may be associated with the development of dry eye syndrome and 
picture of chronic conjunctivitis. However, chronic, low-grade bacterial conjunctivitis and 
dacryocystitis may also lead to a weeping eye.6 Trichiasis (designated TT in the WHO 
simplified trachoma grading scheme), is defined when at least one eyelash rubs on the eyeball 
or evidence of recent removal of in-turned eyelashes. This condition is a potentially blinding 
situation that may lead to chronic conjunctivitis and corneal opacification (Figtures 2-4). 
Trichiasis is due to subconjunctival fibrosis over the tarsal plate that leads to lid distortion. 
Some vision can be restored with the successful correction of trichiasis. Corneal opacity 
(designated CO in the WHO simplified trachoma grading scheme), is defined as easily visible 
corneal opacity over the pupil that is so dense that it blurs at least part of the pupillary margin 
when it is viewed through the opacity (Figures 2-4). Corneal opacity or scarring reflects the 
prevalence of vision loss and blindness resulting from trachoma.11 This condition includes 
pannus, epithelial vascularization, and infiltration only if it involves the central cornea. 
 
 
Fig. 3. An elderly patient with old trachomatous  corneal scarring and chronic conjunctivitis 
due to abnormalities of eyelids 
 
 
Fig. 4. Patient with long-standing bilaterl trachomatous scarring and left-sided nasolacrimal 
duct obstruction causing chronic conjunctivitis 
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2.3 Epidemiology of trachomatous conjunctivitis 
Despite the fact that trachoma has been eradicated from the well-developed countries of the 
World, it still persists in hot, dry regions throughout many parts of Africa, Southern Asia, 
Middle East, Brazil, Mexico and some parts of Australia. 12-15 According to some rough 
estimates, worldwide, trachoma infects 84 million people in 55 countries, blinding over 8 
million.16 According to the WHO estimates, if appropriate measures are not taken, over 75 
million may become legally blind over the next twenty years.  
Trachoma is caused by the eye to eye transmission of infection with C. trachomatis. Flies are 
considered a major factor in the spread of trachoma in many parts of the World.17 Flies may be 
more attracted to children with eye discharges or nasal discharges in the setting of dirty 
environment. Spread of active trachomatis cases can be reduced by controlling the population 
of flies in the known endemic areas.18,19 Over 50% of the household of an infant infected with 
trachomatous infection may have active trachoma. Cases of active trachoma may be 
predominantly clustered in families who share communal housing of interconnecting roof 
spaces through which flies could freely fly. Obviously a close contact with infected ocular 
secretions within the family is considered to be a significant channel of trachoma transmission. 
Chronic infection in older women from repeated exposure from their children may be the 
reason for severe trachomatous scarring, dry eye syndrome and chronic conjunctivitis.20 In the 
endemic trachoma areas such as North Africa, the Middle East and northern India, most 
infants become infected by age 2 or 3 and the condition is primarily a disease of childhood.21-23  
3. Differential diagnoses for trachomatous conjunctivitis 
The differential clinical diagnosis for C. trachomatis conjunctivitis may include adult 
inclusion conjunctivitis, adenovirus conjunctivitis, herpes simplex virus conjunctivitis, 
vernal conjunctivitis, other bacterial conjunctivitis, toxic follicular conjunctivitis, ligneous 
conjunctivitis and allergic conjunctivitis (Figures 5-7).24 Patients having inclusion  
 
 
Fig. 5. A young patient with ligneous conjunctivitis 
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conjunctivitis may present with a history of a red, uncomfortable eye with a mucupurulent 
discharge. On examination, one may find signs of large lymphoid follicles and 
conjunctivitis.25,26 Majority of these patients have associated urinary tract infections. 
Chlamydial inclusion conjunctivitis is caused by genital tract serotype D-K of C. 
trachomatis.25 It is thought that eye is infected through transmitting organisms from genital 
tract secretions by the hands.27 Conjunctival chlamydial infection can be demonstrated by 
staining a conjunctival smear with C. trachomatis-specific fluorescent monoclonal antibody, 
or by the use of commercial nucleic acid-based diagnostic kits.25 
 
 
Fig. 6. An elderly patient with old trachomatous scarring and recent bacterial conjunctivitis 
 
 
Fig. 7. An older patient having old trachoma and chronic dacryocystitis causing 
mucupurulent discharge 
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4. Workup for trachomatous conjunctivitis 
The laboratory tests for ocular C. trachomatis confirmation for the clinical diagnosis of 
active trachoma conjunctivitis are based on techniques for the nucleic acid amplification 
tests, of which the polymerase chain reaction (PCR) is one example.25,28 These tests have high 
specificity and sensitivity. Patients may have infection for several weeks prior to the 
appearance of any specific clinical signs and symptoms. These patients may have persistent 
conjunctivitis for few weeks to months after the infection may have resolved. Some of the 
other useful techniques for laboratory identification of C. trachomatis include, direct 
fluorescein-labeled monoclonal antibody (DFA) assay and enzyme immunoassay (EIA) of 
smears obtained from conjunctival tissue. These tests are less sensitive than PCR. In Giemsa 
cytology, microscopic examinations of the stained conjunctival scrapings for 
intracytoplasmic inclusions may be useful. 
5. Pathophysiology of trachomatis conjunctivitis  
Chlamydiae are gram-negative, obligate intracellular bacteria. The species C. trachomatis 
causes trachoma and also genital infections (serovars D-K) and lymphogranuloma 
venereum (serovars L1-L3).25 Serovars D-K occasionally cause a chronic follicular 
conjunctivitis that is clinically indistinguishable from trachoma, including follicular 
conjunctivitis with pannus and, at times, conjunctival scarring. However, these genital 
serovars do not typically enter stable transmission cycles within communities. Therefore, 
they are not involved in trachomatous conjunctivitis and blindness.  
Trachomatous infection causes inflammation, that is, a predominantly lymphocytic and 
monocytic infiltrate with plasma cells and macrophages in follicles. The follicles are typical 
germinal centers with islands of intense B-cell proliferation surrounded by T 
cells.29 Recurrent conjunctival reinfection causes the prolonged inflammation that leads to 
conjunctival scarring. Scarring is associated with atrophy of the conjunctival epithelium, loss 
of goblet cells, and replacement of the normal, loose, vascular subepithelial stroma with 
thick compact bands of collagen.  
Active trachoma most commonly occurs in preschool children of both sexes and their (usually 
female) care providers. Trichiasis and blindness may be 2-4 times more common in women 
than men. Trachoma is endemic in parts of Africa, Asia, the Middle East, Latin America, the 
Pacific Islands, and aboriginal communities in Australia.15,16,30,31 In endemic areas, most 
members of nearly all families may have active disease. Active trachoma may be seen in 
clusters in some families. In 1 of 5 families, most children may have active trachoma (as 
opposed to 1 in 5 children in most families). This clustering becomes more apparent in 
communities as the prevalence decreases.5,32 Active disease most commonly occurs in 
preschool children, with the highest prevalence in children aged 3-5 years. Cicatricial disease is 
most common in middle-aged adults. The age group in which cicatricial disease begins to 
appear depends on the intensity of transmission in the community. In areas of extremely high 
recurrent infections, trichiasis may occur in children younger than 10 years of age. Young 
children may have follicular trachoma with intense conjunctival inflammation, while their 
mothers may have trachomatous scarring; and middle-aged patients or grandparents may 
have trichiasis and corneal opacity. Individuals may have episodes of follicular trachoma with 
intense conjunctival inflammation even after cicatricial complications develop. The active 
phase resembles many other diseases in which follicular conjunctivitis is a feature. Without 
laboratory facilities, the diagnosis is solely based on the clinical appearance of active trachoma 
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in someone living in a community where trachoma is endemic or suspected to be endemic. 
Many patients with active trachoma may remain relatively asymptomatic.  
The duration of disease and infection in active trachoma decreases markedly as the child 
grows. More rapid disease resolution is found to be the main source of reduction in the 
prevalence of active trachoma and ocular C. trachomatis infection with age. The serious 
sequelae of repeated infection may result from conjunctival scarring. Although a severe 
primary childhood infection may result in conjunctival scarring, the evidence is that re-
infection is the most important factor. With increasing age, there is an increasing exposure to 
infection and increasing immunity which may also increase the likelihood of severe 
sequelae. Poor hygiene increases the likelihood of a high chlamydial load. In some villages 
of Africa, familial cattle ownership, facial cleanliness and living less than two hours from a 
source of clean water may be associated with reduced severity of trachoma. 33,34 Host genetic 
factors affecting the cellular immune response to trachoma agents may be important in 
determining disease severity.  
In active trachoma, the inflammatory infiltrate is organized as lymphoid follicles in the 
underlying stroma and cytoplasmic inclusion bodies can be seen in the conjunctival 
epithelia. In follicular trachoma (grade TF) there is a strong local IgA antibody response to 
the infecting chlamydiae and this is associated with elevated levels of antibody secreting 
cells with specificity for chlamydial antigens in the blood. However in the most severe cases 
with intense inflammation (grade TI) there is a substantial suppression of chlamydia-
specific antibody secreting cells for all isotypes, including IgA.8,34 The suppression may be a 
contributory factor leading to local tissue damage with ensuing scarring. 
In scarring trachoma there are more marked pathological changes in the tissue of the eye lid. 
These include: subepithelial fibrous membrane formation, squamous cell metaplasia, loss of 
goblet cells, pseudogland formation in the conjunctiva, degeneration of the orbicularis occuli 
muscle fibers, sub-epithelial vascular dilatation and lymphocytic infiltration and localized 
peri-vascular amyloidosis.34,35 Accessory lacrimal glands and the ducts of glands are 
compromised by sub-epithelial infiltration and scarring. Contraction of the sub-epithelial 
fibrous tissue formed by collagen fibers and anterior surface drying are considered some of the 
main factors contributing to the chronic scarring and distortion of the eyelid.36 Ocular C. 
trachomatis infection stimulates local cytokines which favor a strong cell-mediated and pro-
inflammatory response in both the acute active and chronic forms of trachoma.  
6. Ophthalmia neonatorum (neonatal conjunctivitis) 
Often known by its Latin name of Ophthalmia neonatorum, it is conjunctivitis of the eyes of 
the new born caused by bacterial infection. Usually the infection is derived from the 
mother's genital tract at birth, in which case the causative organism is either the gonococcus 
or the genital serotype D to K of C. trachomatis (Figure 8).37,38 Other bacterial species may 
also cause conjunctivitis in the newborn, including Neisseria, Pneumococci, Klebsiella 
Pneumoniae and Streptococcus mitis. Some of these organisms are probably acquired after 
birth, as the mode of delivery has little influence. 
In the developing countries, C. trachomatis is a much commoner cause of sexually acquired 
neonatal conjunctivitis than the Gonococcal conjunctivitis. Approximately a third to a half of 
infants born through a chlamydial infected birth canal may develop neonatal 
conjunctivitis.38 Chlamydial neonatal conjunctivitis is a significant, but little diagnosed 
problem in the developing world. Typically, neonatal chlamydial conjunctivitis has an  
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Fig. 8. New born with neonatal conjunctivitis due to Chlamydia 
incubation period of 10 to 14 days compared with the much shorter 2 to 3 days incubation 
for Gonococcal ophthalmia. The conjunctiva of the eye in these patients may be significantly 
swollen with much mucoid discharge that may be less purulent than that usually seen with 
overt Gonococcal ophthalmia. The infection is particularly common in pre-mature babies, 
who are often born to women at particular risk of C. trachomatis infection.24 Conjunctival 
swab obtained from the cul-de-sac of these patients stained with C. trachomatis specific 
fluorescent monoclonal antibody often shows the presence of chlamydial elementary bodies, 
looking like the "star-spangled sky at night". In neonatal conjunctivitis, the nasopharynx is 
also commonly infected with C. trachomatis, presumably via drainage from the oto-lacrimal 
duct, so it is important to treat the infants with systemic rather than topical antibiotic. If left 
untreated, up-to 20% of infants may develop neonatal pneumonia.39 
6.1 Laboratory diagnosis of neonatal trachomatous conjunctivitis and pneumonia 
A chlamydial aetiology should be considered in all infants aged less than thirty days with 
conjunctivitis. There have been no modern studies of commercial nucleic acid amplification 
based tests for the diagnosis of neonatal conjunctivitis. Commercial tests are not specifically 
licensed for use on ocular specimens from neonates. An alternative is the identification of 
chlamydial elementary bodies by direct immunofluorescence. Swabs should be collected 
from the everted eyelid using a swab. It is important that specimens contain conjunctival 
cells, not just exudates. The diagnosis of neonatal C. trachomatis infection confirms the need 
for treatment of the mother and her sexual partner as well as the infant. 
7. Adult inclusion conjunctivitis 
The trachoma serovars of C. trachomatis and the oculo-genital serovars associated with 
adult inclusion conjunctivitis do not appear to differ greatly in their virulence. In trachoma, 
the complications arise from the fact that, where the disease is endemic repeated infection 
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may be common that may lead to increased severity.  In adult inclusion conjunctivitis 
secondary to genital tract infection, there is not the same likely-hood of re-infection.25 
Furthermore, in developed countries there is a greater likelihood that the infection will be 
treated promptly. Thus conjunctival scarring is rarely a complication of adult inclusion 
conjunctivitis, although micro-pannus, and micro ulceration of the cornea following 
punctate keratitis may occur. 
7.1 Laboratory diagnosis of adult conjunctivitis 
Laboratory testing is usually required to establish, with any certainty, the cause of follicular 
conjunctivitis in the adult. This is because other agents, most notably adenovirus, may cause a 
similar clinical appearance. Very occasionally, adenoviral and chlamydial co-infection occur 
together. This should be considered in patients with prolonged follicular keratoconjunctivitis.40 
8. Treatment 
Prevention of trachoma-related ocular complications may require early intervention and 
treatment. The WHO endorses the SAFE strategy for trachoma control. At the community 
level, adequate water access for personal hygiene, sanitation, and fly control determine the risk 
of endemic trachoma. Infants with untreated chlamydial pneumonia shed C. trachomatis and 
are symptomatic for many weeks. Erythromycin, azithromycin and clarithromycine may be 
effective for halting transmission to the baby and treating neonatal conjunctivitis.41,42 
Prophylaxis, however, may be ineffective in some new born patients. Erythromycin base or 
ethyl succinate 50 mg/kg/day may be given orally divided into four doses daily for 14 days. 
Data on the use of other macrolides (e.g., azithromycin and clarithromycin) for the treatment 
of neonatal chlamydial infection are limited although a short course of azithromycin, 20 
mg/kg/day orally, one dose daily for 3 days, may be effective. 
It is essential that all patients with chlamydial conjunctivitis and their sexual partners be 
examined and treated for concomitant chlamydial genital tract infection.43 Inclusion 
conjunctivitis generally responds well to the kind of regimens of macrolide or doxycycline 
used for treating chlamydial genital tract infection.44 In the case of doxycycline, treatment 
with a weekly dose of 300 mg for three weeks or a daily dose of 1.5 mg/kg for one week 
may produce a clinical and microbiological response in vast majority of patients with adult 
chlamydial conjunctivitis. Mild to moderate papillary responses may persist in some 
patients for several months after completion of their treatment. The best results may be 
obtained with a daily dose of 100 mg Doxycycline for fifteen days, which may produce 
rapid clinical and microbiological response in most of the patients. The use of azithromycin 
for the treatment of trachoma suggests that it is likely to be a convenient and effective drug 
for use in treating adult chlamydial inclusion conjunctivitis.45 
Azithromycin is a long-acting antibiotic that has been widely sold in the United States and 
other industrialized nations since the late 1980s under the name Zithromax. The key to the 
treatment of trachoma is the SAFE strategy developed by the WHO.33 In the SAFE 
strategy. “S” stands for trichiasis surgery. The antibiotics (“A”), facial cleanliness (“F”), and 
environmental improvement (“E”) components of this strategy are described in Medical 
Care. The WHO recommends 2 antibiotics for trachoma control: oral azithromycin and 
tetracycline eye ointment. Azithromycin is better than tetracycline, but it is more expensive. 
National trachoma control programs in a number of countries are beneficiaries of a 
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philanthropic donation of azithromycin. Azithromycin is the drug of choice because it is 
easy to administer as a single oral dose. Its administration can be directly observed. 
Therefore, compliance is higher than with tetracycline and can actually be measured, 
whereas, with the home administration of tetracycline, the level of compliance is unknown. 
Azithromycin has high efficacy and a low incidence of adverse effects. When adverse effects 
occur, they are usually mild; gastrointestinal upset and rash are the most common adverse 
events. Infection with C. trachomatis occurs in the nasopharynx; therefore, patients may re-
infect themselves if only topical antibiotics are used. Beneficial secondary effects of 
azithromycin include its treatment of genital, respiratory, and skin infections.45 
The aim of treatment is to reduce the amount C trachomatis in the infection reservoir in the 
family. Treating an individual and not treating infected family members leaves the 
individual at risk for repeat infection.  All family members, including infants, should be 
treated. The antibiotic of choice for treating active trachoma is azithromycin. The dose for 
children is 20 mg/kg in a single dose; adults receive a single dose of 1 g. The second-line 
treatment is topical tetracycline eye ointment 1%. Topical tetracycline is applied to both eyes 
twice a day for 6 weeks. If the patient lives in a hyperendemic area, the whole district (or 
whole community) is eligible for antibiotic treatment. 
Antibiotic therapy is part of the WHO SAFE strategy for trachoma.46 Azithromycin 
(Zithromax) 1 g PO as a single dose is recommended. Although, plasma concentrations may 
be low, because of long-tissue life and higher tissue concentrations, it may be valuable in 
treating intracellular organisms. For pediatric patients, a dose of 20 mg/kg PO once may be 
sufficient. Current WHO recommendations for antibiotic treatment of trachoma are as 
follows: Determine the district-level prevalence of follicular trachoma in 1- to 9-year-old 
children. If the prevalence is 10% or higher, conduct mass treatment with antibiotic of all 
people throughout the district. If the prevalence is less than 10%, conduct assessment at the 
community level in areas of known disease. If assessment at the community level is 
undertaken in communities where the prevalence of follicular trachoma in 1- to 9-year-old 
children is 10% or more, conduct mass treatment of all people with antibiotics. If assessment 
at the community level is undertaken in communities where the prevalence of follicular 
trachoma in 1- to 9-year-old children is 5% or more but less than 10%, targeted treatment 
should be considered. Targeted treatment involves the identification and treatment of all 
members of any family in whom one or more members have follicular trachoma.47 If 
assessment at the community level is undertaken in communities where the prevalence of 
follicular trachoma in 1- to 9-year-old children is less than 5%, antibiotic distribution may 
not be necessary, though targeted treatment can be considered.  
Epidemiologic studies and community-randomized trials have shown that facial cleanliness 
in children reduces both the risk and the severity of active trachoma.8 To be successful, 
health education and promotion activities must be community based and require 
considerable effort. Environmental change activities may include the promotion of 
improved water supplies and improved household sanitation, particularly methods for safe 
disposal of human feces. These activities should be prioritized. The flies that transmit 
trachoma preferentially lay their eggs on feces lying exposed on the soil. Controlling fly 
populations by spraying insecticide is difficult. Studies on the impact of fly control on 
trachoma have had variable results.  Trials undertaken to evaluate the installation of pit 
latrines suggest that the prevalence of trachoma may be reduced but may not demonstrate a 
statistically significant effect. Nevertheless, the general improvements in personal and 
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community hygiene are almost universally associated with a reduction in the prevalence 
and eventually the disappearance of trachoma. This may be true not only in Europe, the 
Americas, and Australia but also in Africa and Asia. 
8.1 Surgical care 
Eyelid surgery to correct trichiasis is important in people with trichiasis, who are at high-
risk for trachomatous visual impairment and blindness. Eyelid surgery to correct entropion 
and/or trichiasis may prevent blindness in individuals at immediate risk (Figure 9).48-50 
Eyelid rotation limits the progression of corneal scarring. In some cases, it can result in 
improvement in visual acuity due to restoration of the visual surface and reductions in 
ocular secretions and blepharospasm.51 The WHO has produced a training manual on the 
bilamellar tarsal rotation procedure. This procedure involves a full-thickness incision of the 
scarred lid and external rotation of the distal margin by using 3 sutures. In regions where 
access to ophthalmologists is limited, well-trained and well-supported health workers can 
perform bilamellar tarsal rotation. Results of randomized clinical trials have confirmed the 
superiority of this method over other techniques. Even after successful surgery, patients 
remain at risk for recurrence. Therefore, long-term follow-up care and intermittent screening 
are important after surgery. Recurrence rates vary greatly between surgeons. Evidence 
supports the adjuvant use of single-dose azithromycin to patients at the time of surgery. 
Patients experiencing recurrent episodes of chronic dacryocystitis and/or canaliculitis may 
benefit from surgical intervention (Figures 4,7,10). 
 
 
Fig. 9. An elderly patient with old trachomatous scarring and upper eyelid entropion 
causing chronic conjunctivitis 
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Fig. 10. Patient with chronic trachomatous scarring and canaliculitis and conjunctivitis 
9. Trachoma preventive strategies 
In the mid 1990s, WHO announced a program called Vision 2020, to tackle the world's major 
causes of blindness. Approximately 45 million people in the world are blind, with a further 
135 million visually disabled. Some 90% of these people live in the developing world. 
Cataract, trachoma, childhood blindness and onchocerciasis account for roughly 70% of the 
global burden of blindness, much of it preventable.52 Part of this program includes the 
Global Elimination of Trachoma by the year 2020, the acronym for which is GET 2020. Key 
to this has been the international trachoma initiative (ITI), a partnership between the 
pharmaceutical company Pfizer and the Edna MacConnell Clarke Foundation, a 
philanthropic organization. 53 The foundation has already funded much valuable work on 
trachoma field studies and basic science including some key studies which indicated the 
efficacy of simple intervention measures, such as face washing, in the prevention of 
trachoma. Pfizer has provided their anti-chlamydial drug, azithromycin, free of charge for 
use in pilot studies in some countries of trachoma prevention by antibiotic treatment. These 
are key elements in the SAFE strategy for GET 2020. 
Among the SAFE strategy, Surgery (to correct eyelid defects that lead to blindness), 
Antibiotic therapy, Facial cleanliness and Environmental improvement (including clean 
water supplies), surgery and antibiotic therapy dominate most programmes that have been 
implemented.46 Surgery has a sustained effect in preventing an individual going blind, but it 
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has no effect on trachoma transmission. Prophylactic antibiotic reduces the transmission of 
infection but, unless frequently repeated, has no sustained effect on disease eradication.46 Of 
the antibiotics most commonly used, oral azithromycin is far easier to administer and thus 
achieves better patient compliance.23,54 Antibiotic treatment might be successful if it is 
targeted at all children in an endemic area under 10 years of age. Mathematical models 
suggest that antibiotic therapy should be given to communities twice a year in areas with 
hyperendemic trachoma (>30% of children infected) and once a year in communities where 
trachoma is only moderately prevalent (<30% of children infected).47  
Sustainable reductions in transmission may be more likely through the F and E components of 
SAFE. Environmental improvement with improved hygiene, better access to water and better 
sanitation and education reduce trachoma transmission which must eventually lead to the 
disappearance of blinding sequelae. Evidence from intervention studies indicates that the 
promotion of face-washing yields modest gains for intense educational effort, raising the 
question for how long the effect will be sustained once health educators have left a village.  
Other studies have shown that latrines, improved access to water or reduction in eye-seeking 
flies are associated with a lower prevalence of active trachoma or with reduced transmission. 
This suggests that the beneficial effects of a combination of improved water supplies, 
provision of latrines, facial hygiene promotion through established infrastructure and control 
of eye-seeking flies may be long term and sustainable. Each of these interventions offers other 
tangible public health benefits. While the main aim of the SAFE program is to reduce trachoma 
infection to a level where blindness would be minimal, multiple mass antibiotic treatments 
alone may be sufficient to eliminate infection in an area with modest disease. 
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